Bank of New York Mellon Corp. (The) Form 8.3 - Sanofi (3333I)
01 Diciembre 2022 - 10:50AM
UK Regulatory
TIDM0A2V
RNS Number : 3333I
Bank of New York Mellon Corp. (The)
01 December 2022
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF
THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
The Bank of New York Mellon Corporation and its
subsidiaries, 1. BNY Mellon Service
Kapitalanlage-Gesellschaft
mbH, 2. Insight Investment Management (Global) Limited, 3.
The Bank of New York Mellon, 4.
BNY Mellon Investment Adviser, Inc., 5. Mellon Investments
Corporation, 6. Newton Investment
Management Limited, 7. Newton Investment Management North
America, LLC, 8. Lockwood Advisors,
Inc., 9. BNY Mellon Securities Corporation, 10. Pershing
LLC, 11. BNY Mellon Trust of Delaware,
(a) Full name of discloser 12. BNY Mellon, National Association
(b) Owner or controller of interests and short
positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is
insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named. N/A
----------------------------------------------------------
(c) Name of offeror/offeree in relation to whose
relevant securities this form relates
Use a separate form for each offeror/offeree Sanofi
----------------------------------------------------------
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity
of offeror/offeree (Note 1) N/A
----------------------------------------------------------
(e) Date position held/dealing undertaken
For an opening position disclosure, state the
latest practicable date prior to the disclosure 30 November 2022
----------------------------------------------------------
(f) In addition to the company in 1(c) above, is YES, we are reporting in respect to the Offeree Horizon
the discloser also making disclosures in Therapeutics plc and Offeror Amgen
respect of any other party to the offer? Inc.
If it is a cash offer or possible cash offer, state
"N/A"
----------------------------------------------------------
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more
than one class of relevant securities of the offeror or offeree
named in 1(c), copy table 2 for each additional class of relevant
security.
Interests and short positions in the relevant securities of the
offeror or offeree to which the disclosure relates following the
dealing (if any)
(Note 2)
Class of relevant security
(Note 3) Ordinary Shares
Interests Short positions
----------------- -----------------
Number % Number %
---------- ----- -------- -------
(1) Relevant securities owned and/or controlled 10,976,049 0.87%
---------- ----- -------- -------
(2) Cash-settled derivatives 18,000 0.001%
---------- ----- -------- -------
(3) Stock-settled derivatives (including options) and agreements to purchase/
sell
---------- ----- -------- -------
Total 10,976,049 0.87% 18,000 0.001%
---------- ----- -------- -------
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new
securities and any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security securities (Note 5)
Ordinary Shares Purchase 1,285 EUR 86.48
Ordinary Shares Sale 3,822 EUR 86.48
Ordinary Shares Purchase 14,163 EUR 86.48
Ordinary Shares Sale 28,421 EUR 86.48
Ordinary Shares Transfer In 309 N/A
Ordinary Shares Transfer Out 3,196 N/A
Ordinary Shares Sale 139 EUR 86.67
ADR Purchase 319 USD 44.45
Ordinary Shares Sale 6,108 EUR 85.98
ADR Purchase 59 USD 44.72
ADR Transfer Out 72 N/A
ADR Purchase 294 USD 45.35
ADR Sale 6 USD 45.05
ADR Purchase 1,340 USD 45.35
-------------- ------------ ---------------
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price
relevant description e.g. opening/ closing a long/ short position, increasing/ reference per unit
security e.g. CFD reducing a long/ short position securities (Note 5)
(Note 6)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, purchasing, Number Exercise Type Expiry Option
relevant description e.g. selling, varying of price per e.g. date money
security call etc. securities unit American, paid/
option to which European received per unit
option etc.
relates
(Note 6)
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant description exercised securities price per
security e.g. call against unit
option (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of Nature of dealing Details Price per unit (if
relevant e.g. subscription, applicable)
security conversion, exercise (Note 5)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement,
or any agreement or understanding, formal
or informal, relating to relevant securities
which may be an inducement to deal or
refrain from dealing entered into by
the person making the disclosure and
any party to the offer or any person
acting in concert with a party to the
offer.
Irrevocable commitments and letters
of intent should not be included. If
there are no such agreements, arrangements
or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement
or understanding between the person disclosing
and any other person relating to the
voting rights of any relevant securities
under any option referred to on this
form or relating to the voting rights
or future acquisition or disposal of
any relevant securities to which any
derivative referred to on this form is
referenced. If none, this should be stated.
None
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 01 December 2022
Contact name Andrew Weiser
----------------
Telephone number 516-338-3752
----------------
Public disclosures under Rule 8.3 of the Rules must be made to a
Regulatory Information Service.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEDZMGZVMNGZZM
(END) Dow Jones Newswires
December 01, 2022 11:50 ET (16:50 GMT)
Sanofi (LSE:0A2V)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Sanofi (LSE:0A2V)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
